had a strong start to FY20 with cochlear implant units growing 13 per cent in the first half.
The impact of patent litigation expenses and Covid-19 on sales revenue during the second half, however, resulted in the reporting of a net loss of $238.3 million.
The recommencement of surgeries is positive, and the $1.1 billion capital raising has strengthened the balance sheet.
Sales revenue declined 6 per cent to $1.4 billion, with the first half up 9 per cent and second half down 22 per cent.
Reported net loss of $238.3 million includes $416.3 million in patent litigation expenses and $24.2 million in innovation fund gains after-tax.
In March Cochlear suspended the dividend until trading conditions improve.
Shares in Cochlear (ASX:COH)
are trading 8.66 per cent higher at $215.48.